Hopital de la Conception
- Address
- 147 Boulevard Baille, Marseille, 13005, France, 13005 Marseille, France
Immune System Diseases
The research team at Hopital de la Conception is evaluating the real‑world impact of pegcetacoplan in patients with rare kidney conditions such as C3G and primary IC-MPGN. The aim is to understand how this complement inhibitor performs outside controlled trial settings, focusing on safety and effectiveness.
- Real‑world effectiveness of complement inhibition
- Long‑term kidney function outcomes
- Safety monitoring in rare glomerular diseases
Findings from these studies will help guide treatment decisions for patients with immune‑mediated renal disorders across Europe.
Nutritional and Metabolic Diseases
At Hopital de la Conception, investigators are testing tirzepatide to see if it can improve glycemic control in adults with Type 1 Diabetes who are also dealing with Obesity or Overweight. The study seeks to demonstrate superior blood‑sugar management compared with placebo while also addressing weight reduction.
- Dual GIP/GLP‑1 receptor agonist effects on glucose
- Weight management in diabetic adults
- Patient‑reported outcomes on metabolic health
Successful results could expand therapeutic options for metabolic disease management and improve quality of life for affected individuals.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital de la Conception
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Real‑World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex MPGN: Multi‑Country Observational Study | Swedish Orphan Biovitrum AB (publ) | Phase III | Recruiting | Jul 2026 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pegcetacoplan | 1 | Unknown | 2026-07-09 | 2026-07-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.